2. Heart Team, Hôpital Marie Lannelongue, F-92350 Le Plessis Robinson, France
3. Heart Team, CHU Montpellier, F-34000 Montpellier, France
4. -Heart Team, Institut Cœur-Poumons, CHU Lille, F-59000 Lille, France -National Institute of Health and Medical Research U1011, F-59000 Lille, France
5. Heart Team, CH Lens, F-62300 Lens, France
6. Heart Team, Institut Cœur-Poumons, CHU Lille, F-59000 Lille, France
7. Heart Team, CHU Nîmes, F-30000 Nîmes, France
8. Univ. Lille, CHU Lille, EA 2694-Santé publique:épidémiologie et qualité des soins of biostatistics, EA 2694 – Santé publique: épidémiologie et qualité des soins, F-59000 Lille, France
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention and external reviewers - has been published immediately upon acceptance as it was received in the last round of revision. The content of this article is the responsibility of the authors.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
To read the full content of this article, please log in to download the PDF.
Methods and results:From 2010 to 2018, a French multicenter prospective registry included 502 patients with n=374 undergoing TC-TAVR and n=128 TAx-TAVR for symptomatic aortic stenosis. Patients treated through TAx access were matched 1:2 to patients treated through TC route by using propensity score (20 clinical, anatomical and procedural variables) and by date of the procedure. The first outcome was the mortality at 1-month follow-up. The second outcome was 1-month stroke/transient ischemic attack (TIA).In matched-propensity analyses, the incidence of the primary outcome was similar in TAx and TC group (TAx 5.5% vs. TC 4.5%; OR=1.23; 95%CI:0.40-3.70). The secondary outcome was similar in TAx (3.2%) and TC (6.8%; OR=0.52; 95%CI:0.14-1.84). Minor bleeding (2.7% vs. 9.3%; OR=0.26; 95%CI:0.07-0.92) and main access hematoma (3.6% vs. 10.3%; OR=0.034; 95% CI:0.09-0.92) were significantly more frequent with the TC access. One-month clinical efficacy and safety and 1-year mortality did not differed according to different routes.
Conclusions:One-month mortality, 1-month stroke/TIA and 1-year mortality are similar with TAx and TC TAVR. However TC-TAVR is accompanied by more minor bleeding and main access hematoma compared with the transaxillary route.
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com